PLoS ONE · 2023 · 10 citations · 19 references
Veterinary MedicineInfectious DiseasesPreventive MedicineImmunizationInfectious Disease EpidemiologyVaccinologyAdult ImmunizationImmunization EpidemiologyVaccinationVaccine EffectivenessVaccine EfficacyVaccine-preventable DiseasesCase-control Study DesignEffectiveness Against Symptomatic DiseaseEfficacy Against InfectionOverall Vaccine EffectivenessProtective Factor AssessmentSars-cov-2 InfectionVaccination Impact AssessmentVaccination Status Ascertainment
OBJECTIVES: The objective of this study is to estimate the effectiveness of COVID-19 vaccines in people treated within the social security system whose vaccination status was reported to the epidemiological surveillance system. STUDY DESIGN: Case-control study. METHODS: This was a case-control study conducted. The records of individuals with suspected cases of COVID-19 registered in the epidemiological surveillance system between February 1 and June 30, 2021, were studied. RT-qPCR was performed to determine SARS-CoV-2 infection; those with a positive result were considered cases, and those with a negative result were considered controls. The ratio between cases and controls was 1:1.3. The crude and adjusted vaccine effectiveness was considered the prevention of symptomatic infection and death and calculated as the difference between the dose and the risk, with a survival analysis among vaccinated people. RESULTS: A total of 94,416 individuals were included, of whom 40,192 were considered cases and 54,224 controls; 3,781 (4.00%) had been vaccinated against COVID-19. Vaccination also proved to be a protective factor against COVID-19, especially in the population who received a second dose (OR = 0.31; 95% CI 0.28-0.35). With the application of the vaccine, there was a protective effect against mortality (OR = 0.76; 95% CI 0.66-0.87). Disease prevention was higher for the BNT162-2 mRNA vaccine (82%) followed by the ChAdOx1 vaccine (33%). In the survival analysis, vaccination provided a protective effect. CONCLUSIONS: There was a positive impact of vaccines for the prevention of symptomatic COVID-19, with a second dose generating greater efficacy and a reduction in deaths.
19
Merryn Voysey, Sue Ann Costa Clemens, Shabir A. Madhi et al. · The Lancet · 2020 · 5K citations · Full text
Veterinary Medicine, Infectious Diseases, Preventive Medicine +17
Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection
Jennifer M. Dan, José Mateus, Yu Kato et al. · Science · 2021 · 3K citations · Full text
SARS-CoV-2 evolution during treatment of chronic infection
Steven A. Kemp, Dami A. Collier, Rawlings Datir et al. · Nature · 2021 · 1.1K citations · Full text
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Uğur Şahin, Alexander Muik, Isabel Vogler et al. · Nature · 2021 · 833 citations · Full text
Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes
Shengli Xia, Kai Duan, Yuntao Zhang et al. · JAMA · 2020 · 806 citations · Full text